Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

T
Tai, Hung-Liang

Ultragenyx Pharmaceutical
PII-182 - POPULATION PHARMACOKINETICS (PK) AND PK/PHARMACODYNAMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY
Hung-Liang Tai
Favorite
Tang, Fei

Genentech
LB-021 - MORPHINE-METABOLITE POPULATION PHARMACOKINETIC MODELING IN NEONATES WITH NEONATAL OPIOID WITHDRAWAL SYNDROME FOLLOWING ORAL ADMINISTRATION OF MORPHINE.
Fei Tang
Favorite
Tan, Mingliang
PII-185 - A QUANTITATIVE MODELING APPROACH TO PREDICT AVAILABILITY OF GENERIC ORPHAN DRUG PRODUCTS.
Mingliang Tan
Favorite
Tan, Wen Rui

Cincinnati Children Hospital Medical Center
LB-019 - MODEL-INFORMED DOSE OPTIMIZATION FOR PROPHYLACTIC PIPERACILLIN-TAZOBACTAM IN PERIOPERATIVE PEDIATRIC PATIENTS.
Wen Rui Tan
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
OAI-003 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Zachary Taylor
Favorite
PII-071 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Zachary Taylor
Favorite
Thiagarajan, Kannan

Vantage Research Inc
PII-215 - EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL
Kannan Thiagarajan
Favorite
Thompson, Corbin

Clinical Pharmacology Modeling and Simulation, Amgen
PII-063 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Corbin Thompson
Favorite
Tiitto, Ville

University of California, San Francisco
PII-122 - INCREASED DOSE CORRECTED AUC FOLLOWING SLOW SUBCUTANEOUS, INTRAMUSCULAR AND ORAL VERSUS INTRAVENOUS BOLUS HUMAN DRUG DOSING AND ITS POTENTIAL FOR INCREASED DOSE CORRECTED PHARMACODYNAMIC EFFECTS.
Ville Tiitto
Favorite
Tippin, Tim

Chimerix, Inc.
PII-124 - METABOLISM AND DISPOSITION OF [14C]-ONC201 (DORDAVIPRONE) IN HEALTHY ADULT PARTICIPANTS
Tim Tippin
Favorite
PII-164 - ASSESSING CYTOCHROME P450 DRUG INTERACTION RISK FOR ONC201 USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Tim Tippin
Favorite
Tran, Clayton

University of California, San Diego
PII-083 - PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.
Clayton Tran
Favorite
Tran, Lana

Pfizer, Inc.
PII-157 - THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, IN HEALTHY ADULT PARTICIPANTS.
Lana Tran
Favorite
Tran, Tony

ORISE
PII-192 - SAFETY CONSIDERATIONS OF SUBJECT POPULATION SELECTION IN BIOEQUIVALENCE STUDIES FOR GENERIC DRUG DEVELOPMENT.
Tony Tran
Favorite